Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01115244 · ClinicalTrials.gov registry record · Phase 4
Use of Dapsone Gel, 5% for Treating Dermatitis Herpetiformis
A Phase 4 study, sponsored by Vanderbilt University Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT01115244 is a Phase 4 study that was terminated before completion, run by Vanderbilt University Medical Center. The registered enrollment target is 1 participants.
The verdict
NCT01115244, a Phase 4 study, was terminated before completion, sponsored by Vanderbilt University Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy of dapsone gel, 5% in the treatment of dermatitis herpetiformis. The primary efficacy end point will be the proportion of patients achieving success based on mean % reduction from baseline in total lesion counts at week six. Success for lesion reduction will be defined as statistically greater mean percent reductions at week six in the dapsone gel-treated extremity compared with the control extremity of each patient.
Interventions
- DRUG Dapsone gel, 5%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2010-07 |
| Est. Completion | 2012-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01115244
The ClinicalTrials.gov registry entry for NCT01115244 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dapsone gel, 5% is the first listed.
NCT01115244 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01115244 about?
NCT01115244 is a clinical study titled "Use of Dapsone Gel, 5% for Treating Dermatitis Herpetiformis". The primary objective of this study is to evaluate the efficacy of dapsone gel, 5% in the treatment of dermatitis herpetiformis. The primary efficacy end point will be the proportion of patients achieving success based on mean % reduction from baseline in total lesion counts at week six. Success for...
What is the current status of trial NCT01115244?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2010-07. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01115244?
The interventions under investigation include: Dapsone gel, 5% (DRUG).
Who is sponsoring clinical trial NCT01115244?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.